Oxygenta Pharmaceutical Ltd (BSE: 524636) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹179 Cr, it ranks #2,752 by market cap among the 6,197 Indian listed companies on FinBizNet, and #38 of 63 in Pharmaceuticals. At ₹50.77 (as of 16 Nov 2026), the share price is 29.1% below its 52-week high of ₹71.59 and 18.1% above its 52-week low of ₹43.00. The share price is down 24.0% over one year and down 24.6% over three months.
| Current Price | ₹50.77 |
|---|---|
| Market Cap | ₹179 Cr |
| BSE Code | 524636 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | 51.90% |
| Return on Assets | -10.72% |
| 52-Week Range | ₹43.00 – ₹71.59 |
| 1-Year Price Change | -24.0% |
| 3-Month Price Change | -24.6% |
| Beta (1Y) | 0.62 |
| Headquarters | Hyderabad, Telangana |
| Website | www.oxygentapharma.com |
Delivery averaged 98.3% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Oxygenta Pharmaceutical Limited manufactures and sells pharmaceutical, medical, and veterinary preparations in India. It offers active pharmaceuticals ingredients and commercial intermediates. The company was formerly known as S.S. Organics Limited and changed its name to Oxygenta Pharmaceutical Limited in February 2022. Oxygenta Pharmaceutical Limited was incorporated in 1990 and is based in Hyderabad, India.
1. Pharmaceuticals-This segment engages in the manufacture and marketing of bulk drugs and intermediates in India. It produces quinolones, anti-asthmatic, anti-ulcerant, and anti-inflammatory drugs.
1. Manufacturing of Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Oxygenta Pharmaceutical Ltd | ₹179 Cr | n/m | 51.90% | — | -24.0% |
Listed by market capitalisation. Ratios are shown for context only.
Oxygenta Pharmaceutical Ltd is trading at ₹50.77, with a market capitalisation of ₹179 Cr.
Oxygenta Pharmaceutical Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Oxygenta Pharmaceutical Ltd has a return on equity of 51.90%.
Oxygenta Pharmaceutical Ltd is listed on the BSE under the scrip code 524636.
Oxygenta Pharmaceutical Ltd's share price is down 24.0% over one year and down 24.6% over three months. Its 52-week range is ₹43.00 to ₹71.59.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.